314 related articles for article (PubMed ID: 35366187)
1. In Silico and In Vitro Evaluations of Fluorophoric Thiazolo-[2,3-b]quinazolinones as Anti-cancer Agents Targeting EGFR-TKD.
Mir SA; Dash GC; Meher RK; Mohanta PP; Chopdar KS; Mohapatra PK; Baitharu I; Behera AK; Raval MK; Nayak B
Appl Biochem Biotechnol; 2022 Oct; 194(10):4292-4318. PubMed ID: 35366187
[TBL] [Abstract][Full Text] [Related]
2. Exploring binding stability of hydroxy-3-(4-hydroxyphenyl)-5-(4-nitrophenyl)-5,5a,7,8,9,9a-hexahydrothiazolo[2,3-b] quinazolin-6-one with T790M/L858R EGFR-TKD.
Mir SA; Nayak B
J Biomol Struct Dyn; 2023 May; 41(8):3702-3716. PubMed ID: 35343861
[TBL] [Abstract][Full Text] [Related]
3. Design, Synthesis and Antitumor Activities of Novel Quinazolinone Derivatives as Potential EGFR Inhibitors.
Wang J; Huang L; Chen X; Yuan Y; Sun J; Yang M
Chem Pharm Bull (Tokyo); 2022; 70(9):637-641. PubMed ID: 36047235
[TBL] [Abstract][Full Text] [Related]
4. Structural insights into conformational stability and binding of thiazolo-[2,3-b] quinazolinone derivatives with EGFR-TKD and
Ahmad Mir S; Paramita Mohanta P; Kumar Meher R; Baitharu I; Kumar Raval M; Kumar Behera A; Nayak B
Saudi J Biol Sci; 2022 Dec; 29(12):103478. PubMed ID: 36389208
[TBL] [Abstract][Full Text] [Related]
5. Development of adamantane scaffold containing 1,3,4-thiadiazole derivatives: Design, synthesis, anti-proliferative activity and molecular docking study targeting EGFR.
Wassel MMS; Ammar YA; Elhag Ali GAM; Belal A; Mehany ABM; Ragab A
Bioorg Chem; 2021 May; 110():104794. PubMed ID: 33735711
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and preliminary structure-activity relationship study of 3-methylquinazolinone derivatives as EGFR inhibitors with enhanced antiproliferative activities against tumour cells.
Zhang Y; Wang Q; Li L; Le Y; Liu L; Yang J; Li Y; Bao G; Yan L
J Enzyme Inhib Med Chem; 2021 Dec; 36(1):1205-1216. PubMed ID: 34074193
[TBL] [Abstract][Full Text] [Related]
7. Novel 2-(5-Aryl-4,5-Dihydropyrazol-1-yl)thiazol-4-One as EGFR Inhibitors: Synthesis, Biological Assessment and Molecular Docking Insights.
Al-Warhi T; El Kerdawy AM; Said MA; Albohy A; Elsayed ZM; Aljaeed N; Elkaeed EB; Eldehna WM; Abdel-Aziz HA; Abdelmoaz MA
Drug Des Devel Ther; 2022; 16():1457-1471. PubMed ID: 35607598
[TBL] [Abstract][Full Text] [Related]
8. Design, Synthesis, Molecular Docking, and Biological Evaluation of Isatin-Based Fused Heterocycles As Epidermal Growth Factor Receptor Inhibitors.
Kumar A; Kumar B; Bhatia R
Assay Drug Dev Technol; 2023 Jul; 21(5):222-233. PubMed ID: 37439798
[TBL] [Abstract][Full Text] [Related]
9. Design, synthesis and biological evaluation of novel heptamethine cyanine dye-erlotinib conjugates as antitumor agents.
Yang X; Hou Z; Wang D; Mou Y; Guo C
Bioorg Med Chem Lett; 2020 Dec; 30(23):127557. PubMed ID: 32949719
[TBL] [Abstract][Full Text] [Related]
10. Design, synthesis and
Le Y; Gan Y; Fu Y; Liu J; Li W; Zou X; Zhou Z; Wang Z; Ouyang G; Yan L
J Enzyme Inhib Med Chem; 2020 Dec; 35(1):555-564. PubMed ID: 31967481
[TBL] [Abstract][Full Text] [Related]
11. Design, Synthesis and Molecular Docking of Novel Quinazolinone Hydrazide Derivatives as EGFR Inhibitors.
Fang ZY; Zhang YH; Chen CH; Zheng Q; Lv PC; Ni LQ; Sun J; Wu YF
Chem Biodivers; 2022 Jun; 19(6):e202200189. PubMed ID: 35510593
[TBL] [Abstract][Full Text] [Related]
12. Synthesis, antitumor activity and molecular docking study of some novel 3-benzyl-4(3H)quinazolinone analogues.
Al-Suwaidan IA; Abdel-Aziz AA; Shawer TZ; Ayyad RR; Alanazi AM; El-Morsy AM; Mohamed MA; Abdel-Aziz NI; El-Sayed MA; El-Azab AS
J Enzyme Inhib Med Chem; 2016; 31(1):78-89. PubMed ID: 25815668
[TBL] [Abstract][Full Text] [Related]
13. Design, Synthesis, Cytotoxic Evaluation and Molecular Docking of New Fluoroquinazolinones as Potent Anticancer Agents with Dual EGFR Kinase and Tubulin Polymerization Inhibitory Effects.
Zayed MF; Ahmed S; Ihmaid S; Ahmed HEA; Rateb HS; Ibrahim SRM
Int J Mol Sci; 2018 Jun; 19(6):. PubMed ID: 29891789
[TBL] [Abstract][Full Text] [Related]
14. Exploration of thiazolidine-2,4-diones as tyrosine kinase inhibitors: Design, synthesis, ADMET, docking, and antiproliferative evaluations.
Aziz NAAM; George RF; El-Adl K; Mahmoud WR
Arch Pharm (Weinheim); 2023 Mar; 356(3):e2200465. PubMed ID: 36403198
[TBL] [Abstract][Full Text] [Related]
15. Design and synthesis of novel quinazolinone-based derivatives as EGFR inhibitors with antitumor activity.
Sonousi A; Hassan RA; Osman EO; Abdou AM; Emam SH
J Enzyme Inhib Med Chem; 2022 Dec; 37(1):2644-2659. PubMed ID: 36146940
[TBL] [Abstract][Full Text] [Related]
16. Computational Investigation of 1, 3, 4 Oxadiazole Derivatives as Lead Inhibitors of VEGFR 2 in Comparison with EGFR: Density Functional Theory, Molecular Docking and Molecular Dynamics Simulation Studies.
Bilal MS; Ejaz SA; Zargar S; Akhtar N; Wani TA; Riaz N; Aborode AT; Siddique F; Altwaijry N; Alkahtani HM; Umar HI
Biomolecules; 2022 Nov; 12(11):. PubMed ID: 36358960
[TBL] [Abstract][Full Text] [Related]
17. Novel benzothiazole-based dual VEGFR-2/EGFR inhibitors targeting breast and liver cancers: Synthesis, cytotoxic activity, QSAR and molecular docking studies.
Abd El-Meguid EA; Naglah AM; Moustafa GO; Awad HM; El Kerdawy AM
Bioorg Med Chem Lett; 2022 Feb; 58():128529. PubMed ID: 35007724
[TBL] [Abstract][Full Text] [Related]
18. Novel sulphonamide benzoquinazolinones as dual EGFR/HER2 inhibitors, apoptosis inducers and radiosensitizers.
Soliman AM; Alqahtani AS; Ghorab M
J Enzyme Inhib Med Chem; 2019 Dec; 34(1):1030-1040. PubMed ID: 31074303
[TBL] [Abstract][Full Text] [Related]
19. Design, Synthesis, In Vitro Anti-cancer Activity, ADMET Profile and Molecular Docking of Novel Triazolo[3,4-a]phthalazine Derivatives Targeting VEGFR-2 Enzyme.
El-Helby AA; Sakr H; Ayyad RRA; El-Adl K; Ali MM; Khedr F
Anticancer Agents Med Chem; 2018; 18(8):1184-1196. PubMed ID: 29651967
[TBL] [Abstract][Full Text] [Related]
20. Decoding dynamic interactions between EGFR-TKD and DAC through computational and experimental approaches: A novel breakthrough in lung melanoma treatment.
Meher RK; Mir SA; Singh K; Mukerjee N; Nayak B; Kumer A; Zughaibi TA; Khan MS; Tabrez S
J Cell Mol Med; 2024 May; 28(9):e18263. PubMed ID: 38685671
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]